Ligand Pharmaceuticals
LGND
314 hedge funds and large institutions have $3.63B invested in Ligand Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 100 increasing their positions, 103 reducing their positions, and 16 closing their positions.
300% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 16
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
72% more call options, than puts
Call options by funds: $3.51M | Put options by funds: $2.04M
67% more capital invested
Capital invested by funds: $2.18B → $3.63B (+$1.45B)
16% more funds holding
Funds holding: 271 → 314 (+43)
5.2% more ownership
Funds ownership: 99.5% → 104.7% (+5.2%)
3% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 103
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$64.1M |
| 2 |
Goldman Sachs
New York
|
+$45.2M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$33M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$30M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$22.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$26.8M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$26M |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$9.34M |
| 4 |
Impax Asset Management Group
London,
United Kingdom
|
-$8.92M |
| 5 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
-$8.64M |
LGND Hedge Fund Activity: Q3 2025 in Review
314 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2025, worth a combined $3.63B — up 67% from $2.18B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new LGND positions and 16 closed out — a net gain of 48 holders — while 100 added to existing stakes and 103 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $64.1M. The largest seller was Dimensional Fund Advisors, cutting an estimated $26.8M.
- 314 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2025, up from 271 in Q2 2025.
- Funds reported $3.63B of Ligand Pharmaceuticals stock for Q3 2025, up 67% quarter-over-quarter.
- 64 funds opened new Ligand Pharmaceuticals positions in Q3 2025 and 16 closed out, a net change of +48 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2025 was Fidelity Investments, an estimated $64.1M added.
- The largest Ligand Pharmaceuticals seller in Q3 2025 was Dimensional Fund Advisors, an estimated $26.8M sold.
Based on aggregated 13F filings for Q3 2025.